Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options.
Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells.
Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
Location: United States, Pennsylvania, Philadelphia
Employees: 1-10
Total raised: $24M
Founded date: 2020
Founders name: Bryan Kim
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.07.2023 | Seed | $17M | - |
| 28.02.2023 | Seed | $7M | - |
Persons 8
| Date | First Name | Last Name | Title | Location | |||
| - | Elizabeth | Morales | Associate ... | linkedin.c... | - | e*********... | - |
| - | Kaci | Crawford | Associate ... | linkedin.c... | - | k*********... | - |
| - | Bryan | Kim | CEO / co-f... | linkedin.c... | - | b*******m@... | - |
| - | Mala | Talekar | Vice Presi... | linkedin.c... | - | m*********... | - |
| - | Raymond | Luke | Director, ... | linkedin.c... | - | r*********... | - |
| - | Calvin | Rhee | Chief Oper... | linkedin.c... | - | c*********... | - |
| - | Pavel | Aprelev | Director o... | linkedin.c... | - | p*********... | - |
| - | Sara | Weiss | Senior Vic... | linkedin.c... | - | s********s... | - |
Mentions in press and media 10
| Date | Title | Description |
| 06.05.2024 | Verismo Therapeutics Announces Upcoming Presentation at ASGCT 2024 | PHILADELPHIA, May 6, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that an abstract has been accepted for oral presentation at the upcoming Americ... |
| 08.04.2024 | Verismo Therapeutics Announces Upcoming Presentation at AACR 2024 | PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that an abstract has been accepted for poster presentation at the upcoming Am... |
| 03.11.2023 | Verismo Therapeutics Announces Upcoming Presentation at SITC 2023 | PHILADELPHIA, Nov. 3, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology today announced that it will be presenting at the upcoming Society for Immunotherapy of Cancer 38th... |
| 20.07.2023 | Cancer-fighting Verismo Therapeutics raised $17M in another pre-Series A | University of Pennsylvania spinout Verismo Therapeutics announced this week that it raised $17 million in a second pre-Series A round. The news comes just five months after the company, which develops therapeutics to improve persistence and... |
| 18.07.2023 | Verismo Therapeutics Nabs $17M Pre-Series A | PHILADELPHIA, PA, Verismo Therapeutics today announced it has raised $17 million in a second pre-Series A financing round. >> Click here for more funding data on Verismo Therapeutics >> To export Verismo Therapeutics funding... |
| 18.07.2023 | Verismo Therapeutics Raises $17M in Second Pre-Series A Funding | Verismo Therapeutics, a Philadelphia, PA-based clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, raised $17M in a second pre-Series A financing round. The round was co-led by DongKoo Bio, HLB ... |
| 28.02.2023 | Verismo Therapeutics Raises $7M in Pre-Series A Funding | Verismo Therapeutics, a Philadelphia, PA-based clinical-stage CAR T company, raised $7M in pre-Series A financing round. The round was led by BRV Capital Management, joined by Ignite Innovation. The financing will support continued advancem... |
| 28.02.2023 | Verismo Therapeutics Inks $7M Pre-Series A | PHILADELPHIA, PA, Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced a $7 million pre-Series A financing round. >> Click here for more funding d... |
| - | Verismo Therapeutics | - |
| - | Verismo Therapeutics: Penn Spinout Company Raises $17 Million Funding Round | Verismo Therapeutics – a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology – recently announced it has raised $17 million in a second pre-Series A financing round. The funding round will suppor... |